|
Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC. |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
Patents, Royalties, Other Intellectual Property - Have a pending patent " Assay for detection of androgen receptor variants".This application claims benefit of priority to the filing date of U.S. Provisional Application Ser. No. 62/634,226, filed February 23, 2018, |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Leadership - Capio BioSciences |
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Pfizer; Physicans' Education Resource; Propella Therapeutics; RevHealth; Sanofi |
Speakers' Bureau - Bayer; Exelixis; Sanofi |
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst) |
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi; UroToday |
|
|
Research Funding - Lilly (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Sanofi |
Consulting or Advisory Role - AstraZeneca; Sanofi |
Research Funding - AstraZeneca; Sanofi |
Patents, Royalties, Other Intellectual Property - Novartis |
Travel, Accommodations, Expenses - AstraZeneca; Moderna Therapeutics |
|
|
Consulting or Advisory Role - Genesis Pharma |
|
|
|
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi |
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Lilly; Merck; Sanofi |
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst) |
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen |
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi |
|
|
Consulting or Advisory Role - AstraZeneca; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Zenith Epigenetics (Inst) |
|
|
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar |
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst) |
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead |
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi |
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics |
|
|
Stock and Other Ownership Interests - OneThree Biotech |
Consulting or Advisory Role - Champions Oncology |
Research Funding - AstraZeneca; Johnson & Johnson |
|
|
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dendreon; FORMA Therapeutics; Janssen; Merck; Pfizer |
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); FORMA Therapeutics (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst) |
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc |
|
|
Employment - Novartis (I) |
Stock and Other Ownership Interests - Novartis (I) |
Patents, Royalties, Other Intellectual Property - International Patent Application DOCKET NO. 1676.083WO1 “Identifying Taxane Sensitivity in Prostate Cancer Patients” (Giannakakou, Plymate, co-inventors) |